Consegna has sold its Linguet technology to Imugene; Intellipharmaceutics settles patent litigation with AstraZeneca;

> Consegna has sold its Linguet technology to Imugene in exchange for a 29% shareholding. Article

> Intellipharmaceutics has settled all outstanding patent litigation with AstraZeneca ($AZN) over the generic version of AZ's Seroquel XR, an extended-release formulation of quetiapine. Press release

> The FDA has accepted NuPathe's ($PATH) resubmission of Zelrix, its migraine patch; the target date for the FDA to complete its review of the NDA is Jan. 17. Press release

> BioAlliance Pharma has received a U.S. patent for Sitavig, a tablet that sticks to the upper gum and delivers acyclovir to treat recurrent cold sores (labial herpes). Article

> Laser-engineered dissolving microneedles could deliver nadroparin. Abstract

> BD Medical's new needle aims to improve performance and patient comfort. Press release

> Bio-Path has started enrollment of a fourth cohort of a Phase I trial of liposomal Grb-2 for leukemia. Press release

> Diabetology to develop oral insulin for India. Press release

And Finally… Alexza's ($ALXA) CEO has high expectations of receiving FDA approval for Adasuve, its inhaled antipsychotic. Article

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.